Search results for: Oncology
Filter search results
The WHO Technical Report on the Pricing of Cancer Medicines: Missing a Central Role for Value Assessment
8 April 2019
…by use of value-based assessment of health and health-related outcomes and by value-based pricing. Additional incentives may be needed for ultra-orphan drugs in oncology and other diseases. Effective management of…
Recommendations for Making Outcome-based Payments a Reality in the NHS: An Application to Cancer Drugs
21 February 2019
…Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology. OHE Consulting Report. RePEc. Towse, A. and Garrison, L., 2017. Value assessment in precision cancer…
Comparing the Cancer-Specific EORTC-8D and the Generic EQ-5D-3L
4 January 2017
…life gains. Reference: Lorgelly, P.K., Doble, B., Rowen, D. Brazier, J., 2016. Condition-specific or generic preference-based measures in oncology? A comparison of the EORTC-8D and the EQ-5D-3L. Quality of Life Research. …
What are the Economic Implications of Moving Away from Paying a Single Price for a Single Drug?
9 July 2018
…progress stimulates competition and often leads to several products coming to market in a therapy class. This is particularly the case in recent developments in oncology. We propose that a…
New NICE Manual for Health Technology Evaluations: A Critical Discussion on the Most Relevant Changes (or Lack Thereof)
23 February 2022
…in oncology; and clarify the meanings of absolute and proportional shortfall with examples, in early stages of the review). OHE has responded to both consultations, and in a previous blog,…
Around The World in HTAs: Italy – What’s Next?
20 April 2023
…Reimbursed by the Italian National Health Service. Pharmacoeconomics. 2023 Jan;41(1):107-117. Russo, P., Marcellusi, A., Zanuzzi, M., et al. Drug Prices and Value of Oncology Drugs in Italy. Value Health 2021;24(9):1273-1278. Latest…
Patricia Cubi-Molla
4 September 2015
…Health Technology Assessment (HTA), and public-sector resource allocation, including efficiency, inequalities, and priority-setting. She has examined global developments in HTA methods and contributed to studies on decision-making for innovative health technologies, oncology, primary care, climate…
Chris Skedgel
15 July 2019
…He has been a Lead Economic Reviewer for the pan-Canadian Oncology Drug Review (pCODR) and the Canadian Common Drug Review (CDR) and has led the development of NICE submissions in…
Priscila Radu
20 September 2021
Priscila Radu has published research on various health economics topics, including changes in HTA methods in several regions, assessment pathways for precision oncology, and regulatory landscape of digital health in…